zurück

Selinexor (multiple myeloma, ≥ 1 prior therapy, in combination with bortezomib and dexamethasone)

 

Subject:

  • Active Substance: Selinexor
  • Name: Nexpovio®
  • Therapeutic area: Multiple myeloma
  • Pharmaceutical company: Stemline Therapeutics B.V.

 

Time table:

  • Start: 01.10.2022
  • Publication of assessment: 02.01.2023
  • End of public hearing: 23.01.2023
  • Final decision by G-BA: middle of March 2023

 

Comparative therapy:

  • Bortezomib + pegylated liposomal doxorubicin OR
  • Bortezomib + dexamethasone OR
  • Lenalidomide + dexamethasone OR
  • Elotuzumab + lenalidomide + dexamethasone OR
  • Carfilzomib + lenalidomide + dexamethasone OR
  • Carfilzomib + dexamethasone OR
  • Daratumumab + lenalidomide + dexamethasone OR
  • Daratumumab + bortezomib + dexamethasone